Bristol-Myers Squibb Company (BMY)

Rating: HOLD

HOLD (5-tier) · income compounder · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -2% vs spot
• Monte Carlo median implies -11% vs spot
• DCF fair value implies -11% vs spot — but this is terminal-value sensitive (exit-multiple $52 vs Gordon $98, 90% apart), so it carries less weight
• Bear case (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) downside is -56% vs spot
• Net: reward/risk of 0.1× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $57.62 (Alpha Vantage close, 2026-06-27) BMY trades on roughly 9x forward earnings against a peer median near 23x. The market is pricing a shrinking earnings base: Eliquis and Opdivo lose exclusivity over 2026-2028, IRA-negotiated pricing bites from 2026, and net debt of $34.9bn limits the firepower to buy replacement revenue. The engine's view is that the discount is largely deserved rather than anomalous: the probability-weighted target of $57.15 sits at spot, the Monte Carlo median of $51.57 and the DCF anchor of $51.63 sit below it, and 76% of simulated variance loads on the multiple rather than on growth or margin. Peer-multiple anchors above $120 are treated as unreliable for a company entering a cliff. The HOLD rating follows: there is no margin of safety at spot, but a 4.6% dividend yield and a 35% base-case probability that the pipeline offsets LOE argue against selling into weakness. The most damaging risk is the 20% structural path, in which earnings and the multiple compress together toward $25 — below the 52-week low of $41.46.

The dashboard below is the whole argument on one page: spot ($58) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural case is mechanical, not speculative. Eliquis and Opdivo — the two largest revenue lines — face exclusivity loss through 2026-2028, and Eliquis already carries an IRA-negotiated price from 2026. If the growth portfolio scales more slowly than legacy revenue erodes, the top line declines rather than plateaus, and a largely fixed R&D and SG&A base turns modest revenue erosion into severe margin deleverage. With net debt of $34.9bn, management cannot buy its way out at scale without stressing the balance sheet or the dividend. The market would then stop valuing BMY on current earnings and start valuing the post-cliff trough, compressing the multiple toward mid-single digits. Falling earnings on a falling multiple produce the $25.15 structural target, below the 52-week low of $41.46.

Key Debate

P/E Multiple explains 76% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.63 vs analyst floor +0.00 → delta +0.63 (n=26 mgmt / 11 Q&A; 93th pctile across the S&P book, z +1.4).

Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).

News (last 365d, 1000 articles): avg ticker sentiment +0.17 (bullish 15% / bearish 2%)

Scenario Analysis

The tree runs from a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($26) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($100); the probability-weighted blend (PWEV $57) is -2% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $26). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 25.15; probability: 0.2.
• Pipeline Setback / Pricing Pressure (17%, $42). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising. Drivers — implied_target: 42.7; probability: 0.17.
• Base — Pipeline Offsets LOE (35%, $58). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns. Drivers — implied_target: 59.31; probability: 0.35.
• Growth — Launch / Indication Expansion (20%, $80). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 80.07; probability: 0.2.
• Bull — Blockbuster / Pipeline Re-Rate (8%, $100). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion. Drivers — implied_target: 101.12; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

peer P/E re-rate excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $51 and 37% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (76% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 8x terminal FCF multiple → $52. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 23.0x) implies $146. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 167% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Pharma

This name sits in the Health Pharma as a biopharma. drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: LLY (biopharma) · JNJ (biopharma) · ABBV (biopharma) · MRK (biopharma) · AMGN (biopharma) · GILD (biopharma) · PFE (biopharma) · VRTX (biopharma) · BMY (biopharma) · REGN (biopharma) · BIIB (biopharma) · INCY (biopharma) · VTRS (biopharma)

Mapping note: name-level 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' (20%) + 'Pipeline Setback / Pricing Pressure' (17%) map to cluster Patent Cliff / IRA Pricing Erosion (37%); name-level 'Growth — Launch / Indication Expansion' (20%) + 'Bull — Blockbuster / Pipeline Re-Rate' (8%) map to cluster Upside — Launches / Pipeline Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Patent Cliff / IRA Pricing Erosion () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_pharma cycle is the shared macro driver. Driver — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $57B + PV(terminal) $84B = EV $141B; + net cash → equity $106B ÷ diluted shares 2.05B = $52/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $98/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 35% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $146; EV/Rev → $123.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Biopharma multiple (AI re-rating) (base 9x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1.1% of revenue; cash conversion (OCF/NI) 201% — cash-backed.

Catalyst Calendar

• 2026-07-30 (~22d) — Quarterly earnings — est. EPS $1.62 (AV EARNINGS_CALENDAR)
• 2026-09-15 (~69d) — IRA Medicare price-negotiation impact effective on Eliquis (authored)
• 2026-11-05 (~120d) — Phase-3 readouts on lead growth-portfolio assets (Cobenfy expansion / Camzyos label extension) (authored)
• 2027-04-30 (~296d) — Generic Eliquis US entry / at-risk launch window (authored)

Forecast Track Record

• EPS surprise: beat 100.0% of the last 8 quarters; average surprise +17.1%.

Competitive Moat

Narrow moat. Patent-protected molecules confer temporary pricing power, not a durable franchise: each key asset (Eliquis, Opdivo) loses exclusivity on a known clock, so the moat is a decaying option, not a perpetuity. If the pipeline fails to replace the ~$25bn LOE hole the terminal multiple is not justified above the ~9x it already trades at and should not re-rate toward the 15-16x pharma-compounder level; a re-rate above 12x is falsifiable only by durable post-2028 top-line growth.

Moat sources:

• Patent + regulatory data-exclusivity on Eliquis/Opdivo (finite, expiring 2026-2028)
• FDA approval barriers and clinical-trial cost as an entry deterrent for novel MoAs
• No network/switching-cost moat - physicians switch on efficacy and formulary economics
• R&D scale (~$10bn/yr) as a partial, non-durable moat contingent on pipeline productivity

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 9.4× forward EPS, vs the house DCF terminal 8.0×, and a peer median 23.0×. The house DCF sits 11% below spot, so the market is pricing in more than the house case — roughly 1.0pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 15.7× (simple median 23.0×). Direct peers count 100%, segment 50%, broad 25%.

Valuation-anchor screen: Peer (fwd P/E) (valid but extreme (>100% over median)). Anchor median 56.6. Extreme/excluded anchors carry no headline weight.

Historical-range cross-check: 52-week range $41–$62, centre $51 (-12% vs spot); spot sits at the 79th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Blockbuster / Pipeline Re-Rate): $100.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (17.0); Op margin ±3pp (13.0); Terminal × ±15% (12.0); WACC ±1pp (5.0); Capex intensity ±15% (2.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 8×, FY+5 revenue $57B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Total revenue growth, year on year < 0.5% (midpoint of the 4% base-case and -3% setback-case growth paths) (2 consecutive prints → health_pharma). The base case requires the growth portfolio to more than offset legacy LOE erosion. Two prints of near-flat or shrinking revenue mean erosion is winning and the setback or structural path is in force.
• Non-GAAP operating margin < 28% (midpoint of the 30.4% base-case and 26% setback-case margin paths) (2 consecutive prints → health_pharma). R&D and SG&A are largely fixed through the cliff. Margin below 28% for two prints signals deleverage from revenue erosion or IRA price cuts, breaking the earnings floor the HOLD rating rests on.
• Full-year revenue guidance < $49.0bn, against the current $50.4bn full-year guide (single event → health_pharma). A cut of this size cannot be explained by FX or phasing; it would mark faster Eliquis/Revlimid erosion or a stalled launch curve, moving probability mass from base to setback.
• Pivotal readout or regulatory decision on a lead growth-portfolio asset (Cobenfy label expansion or equivalent) = primary-endpoint miss or complete response letter (single event → health_pharma). The base and growth scenarios assume new launches replace the revenue lost to the 2026-2028 LOEs. A pivotal failure on a lead asset removes the offset and is not recoverable within the forecast window.
• Net debt / EBITDA > 3.0x (versus roughly 2.3x today on $34.9bn net debt and about $15.4bn EBITDA) (2 consecutive prints → health_pharma). Leverage above 3.0x while earnings decline would force a choice between the 4.6% dividend and the business development needed to refill the pipeline, converting a cyclical setback into the structural path.

Fact / Inference / Speculation

• FACT: Spot $58; 52-week range $41–$62; engine rating HOLD; base-case target $57 (-1%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $53 (-8% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $64 (+11% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.